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Abstract
Objective: Rett Syndrome is a progressive neurodevelopmental disorder caused mainly by mutations in the gene encoding
methyl-CpG-binding protein 2. The relevance of MeCP2 for GABAergic function was previously documented in animal
models. In these models, animals show deficits in brain-derived neurotrophic factor, which is thought to contribute to the
pathogenesis of this disease. Neuronal Cation Chloride Cotransporters (CCCs) play a key role in GABAergic neuronal
maturation, and brain-derived neurotrophic factor is implicated in the regulation of CCCs expression during development.
Our aim was to analyse the expression of two relevant CCCs, NKCC1 and KCC2, in the cerebrospinal fluid of Rett syndrome
patients and compare it with a normal control group.
Methods: The presence of bumetanide sensitive NKCC1 and KCC2 was analysed in cerebrospinal fluid samples from a
control pediatric population (1 day to 14 years of life) and from Rett syndrome patients (2 to 19 years of life), by immunoblot
analysis.
Results: Both proteins were detected in the cerebrospinal fluid and their levels are higher in the early postnatal period.
However, Rett syndrome patients showed significantly reduced levels of KCC2 and KCC2/NKCC1 ratio when compared to
the control group.
Conclusions: Reduced KCC2/NKCC1 ratio in the cerebrospinal fluid of Rett Syndrome patients suggests a disturbed process
of GABAergic neuronal maturation and open up a new therapeutic perspective.
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Introduction
Rett syndrome (RTT) is an X-linked neurodevelopmental
disorder with an incidence of 1:10000 live female births and is
one of the leading causes of mental retardation and autistic
behavior in females [1]. Loss-of-function mutations in the gene
encoding methyl-CpG binding protein 2 (MeCP2) cause most
cases of RTT. Individuals affected with RTT experience normal
development up to the age of 6–18 months, at which time they fail
to acquire new skills and enter a period of motor regression [2].
Autistic features are a hallmark of this disorder and epilepsy is
frequent [3]. RTT patient brain does not show obvious signs of
neurodegeneration, atrophy, gliosis, demyelination, or neuronal
migration defects [4,5], suggesting that neurological symptoms
may primarily stem from subtle defects of subcellular compart-
ments such as dendrites, axons, or synaptic structures [6]. MeCP2
is a transcriptional regulatory protein, and in its absence, a large
number of genes exhibit abnormal expression with implications in
the balance between synaptic excitation and inhibition [7,8].
MeCP2 might be particularly important to GABAergic function
and there is evidence that the expression of MeCP2 is
approximatelly 50% higher in GABAergic neurons when com-
pared to non GABAergic neurons. Mice with conditional deletion
of Mecp2 in GABAergic neurons initially show normal behavior
but in the course of development start displaying forepaw
stereotyped movements, compulsive grooming, impaired motor
coordination, learning/memory deficits, abnormal EEG hyperex-
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citability, severe respiratory dysrhythmias and premature lethality
[8].
c-aminobutyric acid (GABA) is the main inhibitory neurotrans-
mitter in the adult brain. During early development, activation of
the chloride- permeable, postsynaptic, GABAA receptors (GA-
BAA-R) can induce depolarization and the basal intracellular
chloride concentration is determinant for the action of GABA in
the developing neurons [9]. Two major contributors to intracel-
lular chloride concentration are NKCC1 (Na+, K+, 2Cl2
cotransporter, that accumulates chloride in the cell), and KCC2
(K+, Cl2 cotransporter, that extrudes chloride). Several lines of
research correlate epileptogenesis with altered function of NKCC1
and KCC2 [10,11]. In vitro, experiments suggest that bumetanide,
a potent NKCC1 inhibitor, can increase GABAergic inhibition, in
combination with phenobarbital [12]. Bumetanide has also been
reported useful in a neonatal patient with seizures [13] and in
autistic children [14].
Moreover, the brain of MeCP2 deficient animal models shows
deficits in brain-derived neurotrophic factor [15] (BDNF), which is
thought to contribute to the pathogenesis of RTT. BDNF can also
promote the functional maturation of GABAA-R mediated
responses by inducing upregulation of KCC2 [16,17,18].
Human age related changes in GABAA-R physiology remain
controversial, although neuropathological studies have already
identified postnatal developmental changes of NKCC1 and KCC2
cortical expression [18]. The detection of synaptic proteins in the
cerebrospinal fluid (CSF) gives us the possibility to indirectly access
synaptic composition and alterations, using the CSF of patients
with disorders related to neurotransmission, with the advantage of
performing these studies in vivo [19].
We hypothesize that changes in BDNF expression levels or the
direct effect of the underlying genetic mutation can interfere with
the normal expression of NKCC1 and KCC2 leading to a
reduction in the KCC2/NKCC1 ratio, characteristic of the
immature GABAergic system. A comparison of NKCC1 and
KCC2 protein levels in the CSF of patients affected with RTT and
a control population was made in order to address this question.
Patients and Methods
Patients and Controls
Sixteen patients with RTT were recruited to this study, aged
between 2 to 19 years at the moment of CSF collection. Patients’
clinical characteristics are summarized in table 1. Patients without
a documented mutation fulfilled clinical criteria for RTT
according to the last updated revision [20]. The control study
was performed in 67 subjects (age range: 1 day - 14 years; mean:
740 days; female: 27; male: 40) whose CSF samples were
submitted to Hospital San Joan de Deu (HSJD) laboratory under
suspicion of viral or bacterial meningitis or encephalitis. Exclusion
criteria were: diagnosis of viral or bacterial meningitis, neurologic
disease, and hematic or xantocromic CSF (blood contamination).
CSF Samples
CSF samples were collected by lumbar puncture as previously
described [21]. They were obtained after parent’s written
informed consent and in accordance with the Helsinki Declaration
of 1964, as revised in 2000. The ethical committee of HSJD
approved the study. After lumbar puncture, the first ten drops
were used for routine cytochemical/microbiological studies and
then CSF was immediately stored in 4 aliquots at 280uC until the
moment of analysis. Biogenic amines metabolites and synaptic
proteins were studied using the following 20 drops.
NKCC1 and KCC2 expression levels were analyzed by western
blot. Twenty mL of CSF were loaded on gel and proteins were
separated on a 10% sodium dodecyl sulphate-polyacrylamide gel
and transferred to polyvinylidene difluoride membrane (Amer-
shamTM HybondTM –ECL, GE Healthcare). Membranes were
blocked in TBST buffer (0.02 M Tris-base, pH7.6, 0.8% NaCl,
0.1% Tween 20) with 5% dry skimmed milk for 60 min at room
temperature. Anti-NKCC1 (1:500; Santa Cruz BiotechnologyH)
and anti-KCC2 (1:500; MilliporeH) antibodies were added and
incubated at 4 uC overnight. Membranes were washed three times
with TBST buffer followed by incubation with appropriate anti-
rabbit (1:3000, PromegaH) IgG secondary antibody at room
temperature for 1 h. The blot was then washed six times with
TBST and signal was revealed with ECL (PierceH ECL Western
Blotting Substract, Thermo Scientific). Relative levels of each
protein were quantified by measuring optical densities (OD) of the
corresponding bands with Quantity OneH V 4.3.1.software.
Statistical Analysis
Statistical analysis was performed using IBM Statistical Package
for the Social Sciences (IBM SPSS Statistics Version 19.0, SPSS
Inc: Chicago, IL). A significance level of.05 was used in all
analyses. Outlier analysis was done taking into account the
primary variable in the study – healthy/RTT. Outliers (defined as
values 1.5 times lower than the 1st quartile or 1.5 times higher
than the 3rd quartile) [22] were found in 8 cases (1 Rett patient, 7
healthy controls) for KCC2/NKCC1 ratio, 4 cases for NKCC1
(1 Rett patient, 3 healthy controls) and in 1 case (healthy control)
for KCC2. Outliers were excluded from the respective analyses.
Non-parametric tests were applied when possible for age,
NKCC1 and KCC2, since the assumption of normal distribution
was not fulfilled for these variables.
Results
Total CSF protein concentration values (M= 33.27, SD= 19.04,
range: 7–73 g/l) were within normal limits according to different
age ranges [23]. Clinical and genetic features of RTT patients are
described in table 1. NKCC1 and KCC2 western blot analysis
were performed on the CSF of controls and RTT patients. CCCs
were detected in the CSF of this population, at the expected
molecular weight (Figure 1A). Considering the reported sexually
dimorphic expression of KCC2 and GABA function in the
substantia nigra [24] it was decided to control for gender in all
reported analysis.
Furthermore, the homogenous distribution of the demograph-
ical variable age was verified with Mann-Whitney Test (U).
Controls (M= 746.00 days, SD= 1075.89) were significantly
(U= 932.00, p,.001) younger than RTT patients
(M= 3444.69 days, SD= 2173.59) therefore we have controlled
for this variable in all reported analysis (table S1).
KCC2 Expression is Decreased in the CSF of Rett
Syndrome Patients
As patients grew older their OD signal of KCC2 in the CSF
decreased. Partial correlation analysis was performed to clarify the
relationship between age and the OD signal of the different
synaptic proteins (NKCC1, KCC2) in each group (RTT,
Controls), controlling for the effect of gender. A negative
correlation between age and the OD signal of KCC2 (r
(74) =2.292, n = 80, p,.05) has been clearly identified in our
data, i.e. as the participants grew older their OD signal of KCC2
decreased, even when controlling for the effect of gender. Meaning
that, KCC2 levels decrease in CSF throughout aging. However,
Cation Chloride Cotransporters in Rett Syndrome
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concerning the OD signal of NKCC1 this correlation did not
reach statistical significance (r (74) =2.207, p..05). Interestingly,
if the effect of gender was not taken into consideration, a strong,
negative correlation between age and the OD signal of KCC2 (rs
(80) =2.509, p,.0001) and NKCC1 (rs (78) = 2.472, p,.0001)
would have been identified in our data, i.e. as the participants
grew older their OD signals of KCC2 and NKCC1 decrease.
Rett Patients Present a Significantly Lower OD Signal of
KCC2 than Healthy Controls (Figure 1B)
To determine whether there were statistically significant
differences in the OD signal of the different synaptic proteins
(NKCC1, KCC2) between healthy controls and RTT patients, a
between-subjects MANCOVA was performed, controlling for the
effects of age and gender. This analysis revealed a statistically
significant difference between healthy controls and RTT patients,
F (1, 73) = 6.99, p,.01, gp
2 = .087 even when controlling for the
possible confounding effects of age and gender. The subsequent
follow-up Univariate ANCOVAs run to specify the characteristics
of this finding revealed that RTT patients presented a significantly
lower OD signal of KCC2 (M= 81383.80, SD= 82370.99; F (1,
76) = 12.28, p,.001, gp
2 = .139) than healthy controls
(M= 692663.52, SD= 425753.91). Notwithstanding, NKCC1 ex-
pression does not differ significantly between patients
(M= 307834.25, SD= 162592.59) and healthy controls,
(M= 608703.27, SD= 416157.33; F (1, 74) = 1.87, p..05).
KCC2/NKCC1 Ratio is Decreased in the CSF of Rett
Syndrome Patients
To determine whether there were significant differences in the
ratio of the two synaptic proteins (KCC2/NKCC1) on the CSF of
the healthy population and RTT patients a between-subjects
Table 1. Clinical and laboratory features of Rett Syndrome patients included in the study.
Age (Years
at CSF
collection) Genetic screening Epilepsy
Medication (when LP
was performed) Respiratory anomalies
KCC2/NKCC1 (optical
densities)
1 2 MECP2 screened, no
alteration found
No NO AED No 36795/310023
2 2 P.Y141X Refractory Epilepsy
Generalized seizures
NO AED No 0/242968
3 2 P.R270X Refractory epilepsy No AED Severe syperventilation bursts
and apneas
0/323889
4 4 P302H, 905C.T Generalized seizures from 2
years of life
No AED Hyperventilation bursts 167071/228307
5 5 P.R306C Epileptic status Generalized
seizures from 4 years of life
VPA Hyperventilation bursts and
apneas
0/169395
6 6 MECP2, CDKL5
screened, no
alteration found
Generalized seizures since 8
years of life
CBZ Hyperventilation bursts 177102/257110
7 7 MECP2, CDKL5
screened, no
alteration found
Reflex seizures Abcences
Atonic seizures
No AED No 28646/296735
8 8 P.R255X Generalized seizures from
2 years of life
VPA Hyperventilation bursts and
apneas
15584/342592
9 9 MECP2, CDKL5
screened, no
alteration found
Refractory epilepsy VPA TPM Severe Hyperventilation and
apneas
0/54010
10 10 P.R306C Absences and partial seizures
from 8 years
CBZ Hyperventilation bursts 155391/621440
11 11 DEL EX.1–2 Generalized seizures from 8
years
No AED Hyperventilation 91959/527745
12 16 MECP2, CDKL5
screened, no
alteration found
Generalized seizures from 11
years of life
No AED (VPA was
withdrawn 2 years
before LP)
Hyperventilation 156883/445649
13 16 MECP2,
CDKL5screened, no
alteration found.
Polymorfism in NTNG1
Generalized and absence
seizures from 14 years of life
VPA CBZ Hyperventilation bursts 164531/259927
14 16 P.R294X Generalized Seizures from 6
years of life
CBZ LEV Hyperventilation bursts 219795/281395
15 18 MECP2, CDKL5
screened, no
alteration found
Partial seizures CBZ Hyperventilation 7000/535292
16 19 P.R294X Partial, secondarily
generalized and absences
CBZ Hyperventilation bursts and
apneas
604155/28867
DEL: Deletion. LP: Lumbar Puncture. AED: Anti epileptic drugs. VPA: Valproic Acid. CBZ: Carbamazepine. LEV: Levetiracetam. TPM: Topiramate.
doi:10.1371/journal.pone.0068851.t001
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ANCOVA was performed, controlling for the effect of age and
gender. This analysis revealed a statistically significant difference
between Healthy controls and RTT patients, F (1, 70) = 26.56,
p,.001, gp
2 = .28 even when controlling for the possible
confounding effect of age and gender (figure 2B and 2C). RTT
patients presented a significantly lower KCC2/NKCC1 ratio
(M= .26, SD= .30) than Healthy controls (M= 1.08, SD= .56).
Even if the effects of age and gender would not have been
controlled for in the analysis the decrease in KCC2/NKCC1 ratio
was still significant (F (1, 70) = 30.08, p= .001, gp
2 = .29).
Discussion
In this study, we demonstrate reduced KCC2 levels and
KCC2/NKCC1 ratio in the CSF of RTT patients. These findings
suggest that altered inhibitory GABA function can underlie the
pathophysiology of RTT and also play a role in the epileptogenesis
of this neurodevelopmental disorder, in which epilepsy is present
in around 70% of patients [3]. Detection of transmembrane
synaptic proteins in the CSF is a useful tool in the study of
neurotransmission disorders, as recently reported by our group
[19]. Despite their low abundance compared to the global CSF
Figure 1. NKCC1 and KCC2 Cotransporters in the CSF of Rett Syndrome (RTT) Patients and Controls. (A) Immunoblot results in RTT
patients and controls. Numbers refer to the patient ID numbers of Table 1. Comparison of patients and age matched controls. (B) Mean Optic
Densities of NKCC1 and KCC2 Cotransporter Proteins for Rett Patients and Controls suggesting discrepant cotransporter levels between Patients and
Controls supported by the respective MANCOVA (F (1, 73) = 6.99, p,.01, gp
2= .087). Error bars represent 95% Confidence Interval. *p,.01.
doi:10.1371/journal.pone.0068851.g001
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proteome [25], the proteins here studied (NKCC1 and KCC2)
were readily detected and at the expected molecular weight.
Harrington and co-workers [26] identified the presence of CSF
membranous nanostructures that can provide an appropriate
environment for transmembrane proteins, which are hydrophobic
in nature. Their morphology is similar to that of synaptic vesicles
and exosomes; their structure resembles that of nanotubules, cell-
to-cell interacting structures that facilitate the selective transfer of
membrane vesicles and organelles but which seem to impede the
flow of small molecules [27]. The intensity and resolution of the
different bands obtained with the immunoblot procedure
(Figures 1A and 2A) strongly supports the applicability of this
analysis in neurochemical research. To our knowledge, this is the
first report of detection of cation chloride cotransporters in CSF.
CSF turnover ratio and the extent of central nervous system cell
death and synaptic pruning can influence circulating protein levels
but these factors are likely to affect both proteins, NKCC1 and
KCC2, equally. During the first months of postnatal life there is a
period of intense synaptogenesis that subsequentially decreases.
This is probably the cause for the reduction of protein levels in
CSF observed during the first year of life. In fact, regarding
transmembrane proteins like NKCC1 and KCC2, we have
observed the same tendency that also was detected with other
synaptic proteins [19]. The same phenomena could explain the
fact that, in the CSF, both cation chloride cotransporters exhibit a
reduction and KCC2 does not increase in the CSF, as was
expected from previous studies in brain tissue [28,29]. Experi-
mental limitations in humans have been an obstacle in obtaining
direct evidence of age-related changes in GABAA-R physiology
[28].
In mice, loss of MeCP2 leads to reduced expression of BDNF
after birth [15] and in humans evidence of BDNF reduction in
RTT has also been detected [29]. The effects of BDNF on
neurotransmission in developing and mature neurons have been
partly associated with the regulation of GABAergic transmission.
Apart from its effects on GABAergic innervation [30], BDNF can
also promote the functional maturation of GABAA-R mediated
responses by inducing upregulation of KCC2 [16,17]. The
imbalance between excitatory and inhibitory functions in RTT
has been associated with reduced BDNF [31] and GABA levels,
decreased expression of GABA receptor subunits [32], reduced
expression of the enzymes glutamic acid decarboxylase 67 and
glutamic acid decarboxylase 65 [8], reduced number of glutama-
tergic synapses [33] and reduced strength of basal inhibitory
rhythms [34]. Moreover, exogenous BDNF has been shown to
rescue synaptic dysfunction in Mecp-2 null mice. However, the
mechanism by which reduced levels of BDNF contribute to disease
and also to the phenotypical rescue is not completely understood
[31].
Our results suggest an immature pattern of GABAergic
neurotransmission in RTT patients, by revealing a dysregulation
on the KCC2/NKCC1 ratio (the two major contributors to
intracellular chloride concentration) and this evidence in humans
is in accordance with the relevance of MeCP2 for GABAergic
function described in animal models [8]. An imbalance between
excitatory and inhibitory synaptic events, in the brain of children
with neurodevelopmental disorders that have epilepsy and autism
as key features, is a postulated general mechanism. Moreover,
KCC2/NKCC1 ratio dysregulation is a particularly interesting
specific molecular change, already described for diseases like
tuberous sclerosis [35].
Conclusions
We describe a significant decrease of KCC2 in the cerebrospi-
nal fluid of Rett patients. A major advantage of doing these in vivo
studies in children with severe neurologic disorders like RTT, is
that it allows to search for disturbances in the normal develop-
mental pattern. Therefore, our findings might have implications
for the understanding of RTT pathophysiology, considering that
KCC2 is a neuronal specific protein with a key role for neuronal
electrical function and structure, properties that are known to be
altered in Mecp2 mutated neurons. Moreover, these results could
bring light to new therapeutic approaches, particularly through the
pharmacological manipulation of the cation chloride cotranspor-
ters. Further studies in the MECP2 knockout model and other
models to study the disease process are needed to explore these
possibilities.
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